Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine
Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1993 |
|---|
| Umfang: |
4 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Annals of hematology - 1955, 66(1993) vom: März, Seite 131-134 |
| Übergeordnetes Werk: |
volume:66 ; year:1993 ; month:03 ; pages:131-134 ; extent:4 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202971783 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202971783 | ||
| 003 | DE-627 | ||
| 005 | 20230506011245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1993 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202971783 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| 264 | 1 | |c 1993 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Jehn, U. |4 oth | |
| 700 | 1 | |a Heinemann, V. |4 oth | |
| 773 | 0 | 8 | |i in |t Annals of hematology |d 1955 |g 66(1993) vom: März, Seite 131-134 |w (DE-627)NLEJ18898836X |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:1993 |g month:03 |g pages:131-134 |g extent:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01697622 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 1993 |c 3 |h 131-134 |g 4 | ||
| matchkey_str |
article:14320584:1993----::hsisuyframnorfatraueekmaihnemdaeoeyo |
|---|---|
| hierarchy_sort_str |
1993 |
| publishDate |
1993 |
| allfields |
(DE-627)NLEJ202971783 DE-627 ger DE-627 rakwb eng Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine 1993 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. Springer Online Journal Archives 1860-2002 Jehn, U. oth Heinemann, V. oth in Annals of hematology 1955 66(1993) vom: März, Seite 131-134 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:131-134 extent:4 http://dx.doi.org/10.1007/BF01697622 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 131-134 4 |
| spelling |
(DE-627)NLEJ202971783 DE-627 ger DE-627 rakwb eng Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine 1993 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. Springer Online Journal Archives 1860-2002 Jehn, U. oth Heinemann, V. oth in Annals of hematology 1955 66(1993) vom: März, Seite 131-134 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:131-134 extent:4 http://dx.doi.org/10.1007/BF01697622 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 131-134 4 |
| allfields_unstemmed |
(DE-627)NLEJ202971783 DE-627 ger DE-627 rakwb eng Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine 1993 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. Springer Online Journal Archives 1860-2002 Jehn, U. oth Heinemann, V. oth in Annals of hematology 1955 66(1993) vom: März, Seite 131-134 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:131-134 extent:4 http://dx.doi.org/10.1007/BF01697622 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 131-134 4 |
| allfieldsGer |
(DE-627)NLEJ202971783 DE-627 ger DE-627 rakwb eng Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine 1993 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. Springer Online Journal Archives 1860-2002 Jehn, U. oth Heinemann, V. oth in Annals of hematology 1955 66(1993) vom: März, Seite 131-134 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:131-134 extent:4 http://dx.doi.org/10.1007/BF01697622 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 131-134 4 |
| allfieldsSound |
(DE-627)NLEJ202971783 DE-627 ger DE-627 rakwb eng Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine 1993 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. Springer Online Journal Archives 1860-2002 Jehn, U. oth Heinemann, V. oth in Annals of hematology 1955 66(1993) vom: März, Seite 131-134 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:131-134 extent:4 http://dx.doi.org/10.1007/BF01697622 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 131-134 4 |
| language |
English |
| source |
in Annals of hematology 66(1993) vom: März, Seite 131-134 volume:66 year:1993 month:03 pages:131-134 extent:4 |
| sourceStr |
in Annals of hematology 66(1993) vom: März, Seite 131-134 volume:66 year:1993 month:03 pages:131-134 extent:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Annals of hematology |
| authorswithroles_txt_mv |
Jehn, U. @@oth@@ Heinemann, V. @@oth@@ |
| publishDateDaySort_date |
1993-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ18898836X |
| id |
NLEJ202971783 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202971783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011245.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202971783</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jehn, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinemann, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">66(1993) vom: März, Seite 131-134</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:1993</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:131-134</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01697622</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">1993</subfield><subfield code="c">3</subfield><subfield code="h">131-134</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ18898836X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0584 |
| topic_title |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
u j uj v h vh |
| hierarchy_parent_title |
Annals of hematology |
| hierarchy_parent_id |
NLEJ18898836X |
| hierarchy_top_title |
Annals of hematology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ18898836X (DE-600)1458429-3 |
| title |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| spellingShingle |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| ctrlnum |
(DE-627)NLEJ202971783 |
| title_full |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| journal |
Annals of hematology |
| journalStr |
Annals of hematology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1993 |
| contenttype_str_mv |
zzz |
| container_start_page |
131 |
| container_volume |
66 |
| physical |
4 |
| format_se |
Elektronische Aufsätze |
| title_sort |
phase-ii study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| title_auth |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| abstract |
Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. |
| abstractGer |
Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. |
| abstract_unstemmed |
Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine |
| url |
http://dx.doi.org/10.1007/BF01697622 |
| remote_bool |
true |
| author2 |
Jehn, U. Heinemann, V. |
| author2Str |
Jehn, U. Heinemann, V. |
| ppnlink |
NLEJ18898836X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| up_date |
2024-07-06T09:25:14.625Z |
| _version_ |
1803821163085824000 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202971783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011245.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202971783</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jehn, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinemann, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">66(1993) vom: März, Seite 131-134</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:1993</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:131-134</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01697622</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">1993</subfield><subfield code="c">3</subfield><subfield code="h">131-134</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.3987446 |